Long-term outcomes of patients with cerebral vein thrombosis: A multicenter study

F. Dentali, D. Poli, U. Scoditti, M. N D di Minno, V. D. Stefano, S. Siragusa, M. Kostal, G. Palareti, M. T. Sartori, E. Grandone, M. C. Vedovati, W. Ageno, Anna Falanga, Teresa Lerede, Marina Bianchi, Sophie Testa, Dan Witt, Katie McCool, Eugenio Bucherini, Elisa GrifoniDaniela Coalizzo, Raffaella Benedetti, Marco Marietta, Maria Sessa, Clara Guaschino, Giovanni di Minno, Antonella Tufano, Sofia Barbar, Alessandra Malato, Mario Pini, Paola Castellini, Stefano Barco, Marisa Barone, Maurizio Paciaroni, Andrea Alberti, Giancarlo Agnelli, Matteo Giorgi Pierfranceschi, Petr Dulicek, Mauro Silingardi, Landini Federica, Angelo Ghirarduzzi, Eros Tiraferri, Vincenzo di Lazzaro, Elena Rossi, Angela Ciminello, Samantha Pasca, Giovanni Barillari, Emanuele Rezoagli, Matteo Galli, Alessandro Squizzato, Alberto Tosetto

Research output: Contribution to journalArticlepeer-review


Background: Little information is available on the long-term clinical outcome of cerebral vein thrombosis (CVT). Objectives and methods: In an international, retrospective cohort study, we assessed the long-term rates of mortality, residual disability and recurrent venous thromboembolism (VTE) in a cohort of patients with a first CVT episode. Results: Seven hundred and six patients (73.7% females) with CVT were included. Patients were followed for a total of 3171 patient-years. Median follow-up was 40months (range 6, 297months). At the end of follow-up, 20 patients had died (2.8%). The outcome was generally good: 89.1% of patients had a complete recovery (modified Rankin Score [mRS] 0-1) and 3.8% had a partial recovery and were independent (mRS 2). Eighty-four per cent of patients were treated with oral anticoagulants and the mean treatment duration was 12months. CVT recurred in 31 patients (4.4%), and 46 patients (6.5%) had a VTE in a different site, for an overall incidence of recurrence of 23.6 events per 1000 patient-years (95% confidence Interval [CI] 17.8, 28.7) and of 35.1 events/1000 patient-years (95% CI, 27.7, 44.4) after anticoagulant therapy withdrawal. A previous VTE was the only significant predictor of recurrence at multivariate analysis (hazard ratio [HR] 2.70; 95% CI 1.25, 5.83). Conclusions: The long-term risk of mortality and recurrent VTE appears to be low in patients who survived the acute phase of CVT. A previous VTE history independently predicts recurrent events.

Original languageEnglish
Pages (from-to)1297-1302
Number of pages6
JournalJournal of Thrombosis and Haemostasis
Issue number7
Publication statusPublished - Jul 2012


  • Anticoagulant treatment
  • Cerebral vein thrombosis
  • Mortality
  • Recurrence

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Long-term outcomes of patients with cerebral vein thrombosis: A multicenter study'. Together they form a unique fingerprint.

Cite this